tbuckley/cabot-search huggingface dataset:
CN-18 * RELATIONSHIPS BETWEEN DOSE INTENSITY, TOXICITY, AND OUTCOME IN OLIGODENDROGLIAL TUMORS (OG) TREATED WITH PCV REGIMEN
Authors: E. Tabouret, G. Reyes-Botero, C. Dehais, M. Daros, M. Barrie, M. Matta, G. Petrirena, D. Autran, A. Duran, C. Boucard, J. Y. Delattre, O. Chinot
Journal: Neuro-Oncology (2014)

BACKGROUND: In grade II and codeleted grade III gliomas, the procarbazine-CCNU-vincristine (PCV) combination increase survival when added to radiotherapy as first line treatment, despite the important toxicity of this treatment schedule. Our objective was to analyze the tolerance, feasibility and impact of dose intensity of the PCV regimen on outcome for patients with OG. METHODS: We retrospectively reviewed all grade III OG patients receiving PCV (CCNU:110mg/m2) who were referred to our two institutions. The total dose and dose adaptation, cycle delay, dose intensity, toxicity and premature discontinuation of CCNU were analyzed. Impact of these factors on patient outcome was evaluated. RESULTS: Between 2007 and 2011, 89 patients received PCV. Only 37% completed 6 cycles, whereas 13.4% prematurely discontinued PCV because of toxicity. Cycle delay and dose reduction were observed for 62% and 70% patients, respectively. Grade 3 and 4 toxicities were observed in 38% and 8% patients, respectively. Among patients who did not progress under PCV regimen, by multivariate analysis, premature discontinuation for toxicity was significantly correlated with poor PFS (p = 0.023, Hazard ratio (HR):2.354) and OS (p = 0.021, HR:5.093). By univariate analyses, absence of CCNU dose adaptation was correlated to poor PFS (p = 0.032). For OS, pejorative factors were high total CCNU dose (p = 0.029), absence of cycle delay (p = 0.009), absence of CCNU dose adaptation (p = 0.020) and grade 3/4 toxicities (p = 0.013). High CCNU dose-intensity tended to poorly impact PFS (p = 0.053) and OS (p = 0.112). By multivariate analysis, absence of CCNU dose adaptation remained significant for PFS (p = 0.001), while OS was negatively impacted by the absence of cycle delay (p = 0.049) and grade 3/4 toxicities (p = 0.045). CONCLUSION: Despite the efficacy of the PCV regimen, significant toxicity is associated with this schedule, which appears to impact its feasibility and efficacy. The optimal PCV schedule should be redefined taking into account this finding.
Abstract P5-15-03: Patient Characteristics and Clinical Outcome of Patients with Secondary Inflammatory Breast Cancer. M.D. Anderson Cancer Center, Retrospective Review
Authors: RH Alvarez, M Cristofanilli, L Hsu, NT Ueno, PA Alizadeh, A Lucci, JM Reuben, TA Buchholz, GN Hortobagyi, V. Valero
Journal: Cancer Research (2010)

Abstract Background: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer accounting for 1 to 5% of all breast cancers (BC). Secondary inflammatory breast cancer (S-IBC) is the development of inflammatory breast cancer clinical featurs such erythema, edema or skin changes that mimic IBC in either a breast that already had cancer or contralateral previously unaffected breast. (Dawood S, 2008). Currently there are sparse available data to help determine whether S-IBC differs from the P-IBC. The purpose of this analysis was to evaluate the clinical outcomes of pts with S-IBC. Methods: This is a retrospective analysis from prospective M.D. Anderson Cancer Center (MDACC) database that includes 522 pts with P-IBC and 44 pts (8.5%) with S-IBC treated between 1988 and 2009 at MDACC. Results: Median age of the S-IBC pts was 54 years (range 25-75); 33 pts (75%) were postmenopausal; 21 pts (47.7%) had hormone-receptor negative and 9 pts (20.5%) HER-2/neu-amplified. 32 pts (72.7%) had S-IBC stage III and 12 pts (27.3%) stage IV disease. The median interval to develop S-IBC from the primary BC was 147 months (mo) (range 4-310). In a cohort of 13 pts with primary BC who received no radiation therapy (RT) all (100%) pts developed S-IBC in the contralateral breast. Among the 33 pts with primary BC who received RT, 13 pts developed ipsilateral S-IBC whereas the remaining 20 pts developed contralateral S-IBC (p = 0.013). Comparing the S-IBC cohort with the P-IBC cohort, we found the rate of pCR to be higher in P-IBC than in S-IBC (13.6% vs. 3.1%; p = 0.09). Both cohorts had similar distribution in race, menopausal status, hormone-receptor and, HER2 status, and nuclear grade. Moreover, the median PFS was 28.4 mo vs. 22.1 mo. for P-IBC and S-IBC, respectively (p = 0.31). The median OS was 59.5 mo and 53.2 mo for P-IBC and S-IBC, respectively (p = 0.17). In a Cox multivariate analysis of the S-IBC cohort, after adjusting for age, ER/PR-status, LVI, nuclear grade and pCR, HER2/neu-amplified disease was associated with shorter RFS (HR 2.19; CI 0.87-5.50; p = 0.001) and the ER-positive group was associated with a marginal increase in overall survival (HR 0.18; CI 0.03-1.02; p = 0.05). Conclusion: In this retrospective analysis, S-IBC was associated with a lower rate of pCR but with similar RFS and OS compared with P-IBC. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-15-03.
Ticrynafen: A New Thiazide-Like but Uricosuric Antihypertensive Diuretic
Authors: Jan Koch-Weser, Edward D. Frohlich
Journal: New England Journal of Medicine (1979)

EVER since the late 1950's, when the oral thiazide congeners were introduced clinically, diuretic therapy has been the mainstay in the treatment of hypertension. Indeed, this class of diuretic agents has been singled out by the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure as the first step in antihypertensive therapy.1 Notwithstanding the importance of this major class of diuretics, the search for improved diuretics and other antihypertensive agents has continued. Diuretic compounds have been synthesized and introduced clinically that can be more effective in patients with chronic renal disease and impaired renal excretory function, . . .
SAT0061 No migration of injected mesenchymal stem cells to arthritic joints
Authors: J. Swart, F. Hofhuis, B. Prakken, F. Broere, A.C. Martens, N.M. Wulffraat
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> MSC's are adult stem cells present in many tissues, potently immunosuppressive, shown to specifically migrate to damaged areas. MSC's have been shown to diminish arthritis in animal models although the mechanism of action remains unclear. <h3>Objectives</h3> To look for specific migration to inflamed joints, in vivo expansion and elimination of local and systemic injected MSC's. <h3>Methods</h3> Groups of 6 mice were injected with human proteoglycan according to the PGIA protocol. MSCs with the GFP-Firefly luciferase fusion gene were used. The mice underwent repeated bioluminescence imaging (BLI) after intraperitoneal (i.p.), intraarticular (i.a.), intravenous (i.v.) or intracardial (i.c.; in the left ventricle) injection of MSCs in doses of 5×10<sup>6</sup> i.p., 2×10<sup>6</sup> i.a., 1×10<sup>6</sup> i.v. or 0.3×10<sup>6</sup> i.c. MSC's were traced a few times per week after the administration of MSC's. <h3>Results</h3> BLI showed that iv administered MSC's aggregated and leading to pulmonary embolism in a substantial proportion of these mice. Injection of MSCs in the left ventricle followed the routes of the large branches of the aorta. At no point the cells were seen to migrate to the joints in any of the mice. In none of the mice the MSC's were visible after 5 weeks. At no point an increase in signal was seen. No difference in elimination rate was seen between allogeneic or syngeneic MSC's (see figure). <h3>Conclusions</h3> At no point MSC's were seen to migrate to the joints after iv or ic injection and in the ip and ia group the cells stayed at the injection site. At no point an increase in signal was seen in any of the mice. In all mice the MSC's were no more visible after 5 weeks. No difference in the elimination rate was observed between allogeneic or syngeneic MSC's. <h3>Disclosure of Interest</h3> None Declared
THE PHENOTYPIC SPECTRUM OF MOST FREQUENT MUTATION RESPONSIBLE FOR THE SHORT QT SYNDROME
Authors: Dan Hu, Jiancheng Zhang, Yang Li, Ryan Pfeiffer, Michael Gollob, Jeff Healey, Daniel Toshio Harrell, Naomasa Makita, Haruhiko Abe, Yaxun Sun, Jihong Guo, Li Zhang, Ganxin Yan, Douglas Mah, Edward Walsh, Harris Leopold, Carla Giustetto, Fiorenzo Gaita, Andrea Mazzanti, Silvia Priori, Charles Antzelevitch, Hector Barajas Martinez
Journal: Journal of the American College of Cardiology (2016)
INCREMENTAL DIAGNOSTIC VALUE OF MICRORNA-208A OVER TROPONIN I IN PATIENTS PRESENTING WITH CHEST PAIN
Authors: Evangelos Oikonomou, Konstantinos Mourouzis, Gerasimos Siasos, Maria Gazouli, Stamatis Tsouroulas, Giorgos Zakinthinos, Sotirios Tsalamandris, Aimilios Kalampogias, Antigoni Miliou, Manolis Vavuranakis, Dennis Cokkinos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2016)
RESIDUAL THROMBUS PATTERN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION CAUSED BY PLAQUE EROSION, PLAQUE RUPTURE, VERSUS CALCIFIED NODULE AFTER ASPIRATION THROMBECTOMY: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Takumi Higuma, Tsunenari Soeda, Masahiro Yamada, Hiroaki Yokoyama, Takashi Yokota, Kei Izumiyama, Fumie Nishizaki, Yoshiyasu Minami, Lei Xing, Hang Lee, Ken Okumura, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2016)
Abstract 4207: Pharmacodynamic comparisons of novel cryobiopsy instrumentation compared to standard techniques through comparative oncology modeling
Authors: Melissa C. Paoloni, Christina Mazcko, Tiziano DiPaolo, Ralph Parchment, Robert Kinders, Joseph Tomaszewski, Chand Khanna
Journal: Cancer Research (2010)

Abstract The development of novel and targeted cancer drugs requires innovative clinical trial designs to define drug (pharmacokinetic) and host (pharmacodynamic) relationships early in the development process. For most new cancer agents there is increased emphasis on pharmacodynamic (PD) endpoints measured in tumor and surrogates as biomarkers of response. Accordingly, novel tissue collection procedures and instruments are needed to ensure that PD endpoint assessments are representative of their actual in vivo “state”. The Cassi Rotational Core Biopsy Device (Cryobiopsy) (Sanarus Medical, Inc, Pleasanton, California) is a biopsy instrument capable of incisional tissue collection and simultaneous freezing. In rodent xenograft models it demonstrated superiority in consistency for tumor analyte detection compared to traditional biopsy techniques. Whether this value would translate to the clinical setting was unknown. Use of naturally occurring cancers in pet dogs provides a model system to validate and optimize instrumentation techniques prior to use in human trials. A prospective clinical trial in dogs with lymphoma was conducted through the National Cancer Institute-Comparative Oncology Trials Consortium (NCI-COTC) to 1) determine if Cyrobiopsy provides sample quality advantages over conventional tru-cut, and open biopsy procedures, and 2) validate a “practice setting” Cryobiopsy Standard Operating Procedure (SOP) that could be followed by multiple users providing consistent high-quality biopsy samples. Ten dogs with newly diagnosed lymphoma enrolled. Cryobiopsy and tru-cut samples were collected in each patient from two lymph nodes in three planes via alternating techniques. A whole lymph node was then removed via excisional biopsy from the same dog. No adverse events were reported with Cryobiopsy or standard biopsy methods. The SOP for cryobiopsy collection of tissues was successfully implemented in a relevant clinical setting. Cryobiopsy collected samples successfully preserved target phospho-proteins (p-AKT: tAKT, p-ERK: tERK, p-MEK: tMEK) collected from tumor tissue. No difference in phospho-protein detection by Western was seen across biopsy techniques. In conclusion, this effort highlights the utility of the comparative approach to model medical device evaluation and PD biomarker assay validation in the clinical theatre. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4207.
Abstract 2697: Functional analysis of metastasis-related microRNA induced by the stromal-cell derived factor (SDF)-1/CXCR4 system in oral cancer.
Authors: Makoto Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi, Tetsuya Tamatani, Hirokazu Nagai, Youji Miyamoto
Journal: Cancer Research (2013)

Abstract We have previously demonstrated that stromal cell-derived factor (SDF)-1/CXCR4 system is involved in the metastatic process of oral cancer. Recently, small non coding RNAs, microRNAs (miRNAs) are involved in the metastatic process of several types of cancers. However, the miRNAs contributed to metastases induced by the SDF-1/CXCR4 system in oral cancer are largely unknown. Thus, we examined the metastasis-related miRNAs induced by the SDF-1/CXCR4 system, using oral cancer cells, B88-SDF-1, which exhibits functional CXCR4 and distant metastatic potential, in vivo. We examined the metastasis-related miRNAs induced by the SDF-1/CXCR4 system by use of a miRNA microarray representing approximately 1700 miRNA. Consequnetly, we identified 4 kinds of upregulated-miRNAs in B88-SDF-1 cells whose functions are unknown. Among these miRNAs, we confirmed the upregulation of miR-5XX in B88-SDF-1 cells by the real-time PCR analysis. Although LNA-based miR-5XX inhibitor did not affect the growth of the cells, it did significantly inhibit the migration of B88-SDF-1 cells. Thus, we examined the target gene(s) of miR-5XX in the SDF-1/CXCR4 system. cDNA microarray analysis revealed that 6 kinds of mRNA containing the predictive binding site of miR-5XX were upregulated by the treatment with miR-5XX inhibitor. Furthermore, gene A mRNA and protein was downregulated in B88-SDF-1 cells, and upregulated by the treatment with miR-5XX inhibitor. These results indicating that SDF-1/CXCR4 system might regulate the metastases of oral cancer by the downregulation of gene A via upregulation of miR-5XX. Citation Format: Makoto Kinouchi, Daisuke Uchida, Nobuyuki Kuribayashi, Tetsuya Tamatani, Hirokazu Nagai, Youji Miyamoto. Functional analysis of metastasis-related microRNA induced by the stromal-cell derived factor (SDF)-1/CXCR4 system in oral cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2697. doi:10.1158/1538-7445.AM2013-2697
Abstract 3002: Multiplexing ChIP-Seq and rapid chromatin preparation from solid mammalian tissues for low cell ChIP assays
Authors: Andreas R. Tobler, Loni Pickle, George Marnellos, Tom Z. Chen
Journal: Cancer Research (2011)

Abstract Currently, the chromatin immunoprecipitation assay (ChIP) is the most powerful method utilized to selectively enrich for DNA sequences bound by a particular protein in living cells. We developed a SOLiD™ ChIP-seq kit, which offers an optimized ChIP workflow and an efficient SOLiD™ ChIP-seq library construction from relatively low cell number samples. ChIP procedure is usually laborious, time consuming, and typically requires large starting cell numbers. We use MAGnify™ Chromatin Immunoprecipitation System, which is suitable for fast enrichment of chromatin complexes and DNA recovery. It is able to use lower starting cell numbers for ChIP and allows faster throughput to investigate different chromatin and transcription time-course events as well as enable antibody screening to determine ChIP compatibility. In addition, we develop a sensitive ChIP-seq library construction procedure which enables users to construct a complex library using as low as 1 ng ChIP DNA. Combining with SOLiD™'s ultra high sequencing throughput, SOLiD™ ChIP-seq offers a highly sensitive, hypothesis-neutral approach to accurately characterize protein-DNA interactions at genome-wide scale. Here we paired the SOLiD™ Fragment Library Barcoding Kit, which enables users to pool fragment libraries prior to emulsion PCR and then conduct multiplexed sequencing analysis, with the SOLiD™ ChIP-Seq Kit to characterize Estrogen Receptor alpha binding sites in breast cancer cells utilizing the SOLiD™ platform. In addition, we demonstrate a novel, rapid, and low input per ChIP tissue collection protocol for researchers utilizing solid mammalian tissue to study protein-DNA interaction via the MAGnify™ ChIP System. The 50 cent assay is reduced to less than 1 cent per reaction and it reduces reported homebrew amount of tissue from approximately 30mg to less than 1mg per ChIP reaction when paired with the powerful MAGnify™ ChIP system. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3002. doi:10.1158/1538-7445.AM2011-3002
Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I‐PRESERVE) trial
Authors: Jane A. Cannon, Li Shen, Pardeep S. Jhund, Inder S. Anand, Michel Komajda, Robert S. McKelvie, Michael R. Zile, Peter E. Carson, John J.V. McMurray
Journal: European Journal of Heart Failure (2016)
Nocturnal Hypoxemia and Associated Electrocardiographic Changes in Patients with Chronic Obstructive Airways Disease
Authors: V. G. Tirlapur, M. A. Mir
Journal: New England Journal of Medicine (1982)

To study the direct effects of nocturnal hypoxemia on the heart, we recorded electrocardiographic tracings and arterial oxygen saturation (SaO2) during the night in patients with chronic obstructive airways disease. In seven "blue-bloater" patients the mean basal SaO2 was less than 80 per cent, and it fell by more than 10 per cent during 29 episodes of transient hypoxemia. Only five such episodes occurred in three of five "pink-puffer" patients. All "blue bloaters" with low basal mean SaO2 had multiple atrial and ventricular premature contractions and a high heart rate at rest; six patients had a prolonged QTc, three had ST-T depression, and one had right-bundle-branch block. Oxygen therapy increased basal mean SaO2, reduced ectopic activity, abolished ST-T changes and bundle-branch block, significantly reduced the resting heart rate and the amplitude of the R and S waves, and shortened the QTc in four non-smokers. These results suggest that sustained hypoxemia contributes to myocardial dysfunction and heart failure in "blue-bloater" patients. (N Engl J Med. 1982; 306:125–30.)
Abstract 5248: A novel ovarian cancer imaging agent based on integrin ligation
Authors: Stephen D. Swenson, Zibo Li, Radu Minea, Francis S. Markland
Journal: Cancer Research (2012)

Abstract Ovarian cancer diagnosis and subsequent evaluation of disease progression is difficult due to the location of tumor mass and access to the organs affected. Ultrasound and surgical exposure are required to confirm disease and response to treatment. In an effort to develop a non-invasive radiologic method for both diagnostic assessment and to follow disease progression we have produced a integrin ligand, vicrostatin (VCN) that can be radiolabeled and imaged upon binding to active integrins over-expressed on the tumor. VCN displays a high affinity for integrins which are active and pivotal in tumor growth and progression. In the present studies we utilized an animal model employing the luciferase expressing cell line OVCAR-3luc. This procedure allows us to observe both the tumor itself in a living animal, and also co-register the PET image with the optical image enabling us to detect tumors in the intraperitoneal (IP) space. For these experiments we injected OVCAR-3luc cells IP and allowed the tumors to age for 28 days. At this point, with no obvious sign of disease, we imaged the tumors using the optical imaging system to detect the presence of luciferase. Since luciferase is only found in the tumor, this enables us to specifically image the tumor. Following these images 64Cu-DOTA-VCN is injected into the tail vein of the study animals and allowed to circulate for 90 minutes. At this time the animal is placed onto the mounting tray of the PET imaging instrument. There is a specific accumulation of 64Cu-DOTA-VCN in an area in the lower abdomen that correlates with a location of luciferase activity seen in the optical image. Both of these positions were confirmed by dissection and exposure of the tumor in the sacrificed animal. Experiments in which a larger number of cells are injected IP produced unusable optical images, as the tumors grew very large and coated much of the surface in the IP space yielding bright and indistinguishable images in the mouse abdomen. One problem of note is the high level of uptake by the kidneys at the 90 minute time point. The kidneys shield the ability to view an ovarian tumor via a dorsal or ventral total slice view. When viewed transversely, there is clear separation between the kidneys and the tumor mass which binds the 64Cu-DOTA-VCN. A three dimensional reconstruction yields a three dimensional model that can be rotated and rendered to observe the position of the tumor in relationship to the kidneys in space. These studies show that VCN can be utilized to image early stage OC and could possibly be used to monitor residual disease after surgical or therapeutic intervention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5248. doi:1538-7445.AM2012-5248
ENTEROSCOPIA DE BALÓN. PRINCIPALES INDICACIONES Y MANEJO DIAGNÓSTICO-TERAPÉUTICO EN LA PATOLOGÍA DE INTESTINO DELGADO EN NUESTRO CENTRO
Authors: L Luzón, R Uribarrena, L Ollero, J Val, A Artal, S Frago, A Pardillos, LM Ruíz, P Camo
Journal: Endoscopy (2014)

Introducción: La enteroscopia de balón (EB), ha demostrado ser superior a la enteroscopia oral de pulsión y permite evaluar el intestino delgado (ID) en su totalidad. Combinando vía oral y anal, las exploraciones completas llegan a 75%. La ventaja fundamental frente a la cápsula es la capacidad de diagnóstico anatomopatológico y terapéutica endoscópica del ID. Los hallazgos más frecuentes en algunas series son las erosiones o úlceras, malformaciones arterio-venosas seguidas de pólipos y tumores.